242 related articles for article (PubMed ID: 23224376)
1. CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary.
Bachmann C; Grischke EM; Fehm T; Staebler A; Schittenhelm J; Wallwiener D
J Cancer Res Clin Oncol; 2013 Apr; 139(4):551-6. PubMed ID: 23224376
[TBL] [Abstract][Full Text] [Related]
2. Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer.
Bachmann C; Grischke EM; Staebler A; Schittenhelm J; Wallwiener D
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1909-16. PubMed ID: 24037487
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and survival outcome in cerebral metastatic breast cancer.
Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
[TBL] [Abstract][Full Text] [Related]
4. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
9. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
14. Reliability of receptor assessment on core needle biopsy in breast cancer patients.
Seferina SC; Nap M; van den Berkmortel F; Wals J; Voogd AC; Tjan-Heijnen VC
Tumour Biol; 2013 Apr; 34(2):987-94. PubMed ID: 23269610
[TBL] [Abstract][Full Text] [Related]
15. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
19. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]